40 related articles for article (PubMed ID: 26345572)
1. [Multiple myeloma with IgH::MYC and multiple extramedullary lesions].
Sasaki Y; Ichikawa S; Sakurai K; Nakamura H; Inokura K; Onodera K; Fukuhara N; Onishi Y; Yokoyama H; Harigae H
Rinsho Ketsueki; 2024; 65(3):147-152. PubMed ID: 38569857
[TBL] [Abstract][Full Text] [Related]
2. [Successful treatment of venous thromboembolism with a Factor Xa inhibitor, edoxaban, in patients with lenalidomide-treated multiple myeloma].
Kawaguchi M; Uchimura N; Okuda Y; Konuma S; Nehashi Y
Rinsho Ketsueki; 2015 Aug; 56(8):1096-9. PubMed ID: 26345573
[TBL] [Abstract][Full Text] [Related]
3. Panobinostat for the Treatment of Multiple Myeloma.
Laubach JP; Moreau P; San-Miguel JF; Richardson PG
Clin Cancer Res; 2015 Nov; 21(21):4767-73. PubMed ID: 26362997
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with bortezomib, continuous low-dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients.
de Waal EG; de Munck L; Hoogendoorn M; Woolthuis G; van der Velden A; Tromp Y; Vellenga E; Hovenga S
Br J Haematol; 2015 Dec; 171(5):720-5. PubMed ID: 26358087
[TBL] [Abstract][Full Text] [Related]
5. Novel therapeutic targets in multiple myeloma.
Cottini F; Anderson K
Clin Adv Hematol Oncol; 2015 Apr; 13(4):236-48. PubMed ID: 26352582
[TBL] [Abstract][Full Text] [Related]
6. Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma.
Duru AD; Sutlu T; Wallblom A; Uttervall K; Lund J; Stellan B; Gahrton G; Nahi H; Alici E
PLoS One; 2015; 10(9):e0138248. PubMed ID: 26378933
[TBL] [Abstract][Full Text] [Related]
7. The possible involvement of JNK activation in the spinal dorsal horn in bortezomib-induced allodynia: the role of TNF-α and IL-1β.
Li ZY; Zhang YP; Zhang J; Zhang SB; Li D; Huang ZZ; Xin WJ
J Anesth; 2016 Feb; 30(1):55-63. PubMed ID: 26373954
[TBL] [Abstract][Full Text] [Related]
8. Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs.
Gooding S; Lau IJ; Sheikh M; Roberts P; Wong J; Dickens E; Bullement A; Elvidge J; Lee D; Ramasamy K
PLoS One; 2015; 10(9):e0136207. PubMed ID: 26367874
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibodies - A new era in the treatment of multiple myeloma.
Jelinek T; Hajek R
Blood Rev; 2016 Mar; 30(2):101-10. PubMed ID: 26362528
[TBL] [Abstract][Full Text] [Related]
10. Treatment options for mantle cell lymphoma.
Smolewski P; Witkowska M; Robak T
Expert Opin Pharmacother; 2015; 16(16):2497-507. PubMed ID: 26360791
[TBL] [Abstract][Full Text] [Related]
11. The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea.
Kim C; Lee HS; Min CK; Lee JJ; Kim K; Yoon DH; Eom HS; Lee H; Lee WS; Shin HJ; Lee JH; Park Y; Jo JC; Do YR; Mun YC
Korean J Intern Med; 2015 Sep; 30(5):675-83. PubMed ID: 26354062
[TBL] [Abstract][Full Text] [Related]
12. Counterpoints: Do patients with multiple myeloma need maintenance treatment? Yes, but the proper candidates and schedule must be determined.
Berenson JR; Andreu-Vieyra C
Clin Adv Hematol Oncol; 2015 Mar; 13(3):163-6. PubMed ID: 26352423
[No Abstract] [Full Text] [Related]
13. Bortezomib in the treatment of mantle cell lymphoma.
Robak T
Future Oncol; 2015; 11(20):2807-18. PubMed ID: 26347482
[TBL] [Abstract][Full Text] [Related]
14. [Relapsed/refractory multiple myeloma with CD138 shedding and formation of extramedullary disease in the common bile duct region presenting as obstructive jaundice].
Yokoyama A; Hosoda T; Shiraishi J; Yamamoto R; Yoneda M; Ohashi K; Okabe T; Kagoo T; Boku S; Ueno H; Yano T
Rinsho Ketsueki; 2015 Aug; 56(8):1089-95. PubMed ID: 26345572
[TBL] [Abstract][Full Text] [Related]
15. [Hepatic hilus extramedullary plasmacytoma diagnosed by endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) biopsy in a relapsed multiple myeloma].
Oyama N; Ise M; Mimura N; Tsujimura H; Sakai C; Kumagai K
Rinsho Ketsueki; 2009 Feb; 50(2):102-6. PubMed ID: 19265303
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic plasmacytoma with biliary obstruction as a manifestation of multiple myeloma relapse.
Castellani L; Burgësser MV; Guanchiale L; Benavidez A; de Diller AB; Basquiera AL; Balderramo D
Gastroenterol Hepatol; 2014; 37(6):357-9. PubMed ID: 24746707
[No Abstract] [Full Text] [Related]
17. Relapse of IgA lambda multiple myeloma presenting as obstructive jaundice and abdominal pain.
Annibali O; Marchesi F; Petrucci MT; Tirindelli MC; Avvisati G
Onkologie; 2009 Mar; 32(3):119-21. PubMed ID: 19295251
[TBL] [Abstract][Full Text] [Related]
18. Primary non-Hodgkin's lymphoma of the common bile duct presenting as obstructive jaundice.
Joo YE; Park CH; Lee WS; Kim HS; Choi SK; Cho CK; Rew JS; Kim SJ; Maetani I
J Gastroenterol; 2004 Jul; 39(7):692-6. PubMed ID: 15293142
[TBL] [Abstract][Full Text] [Related]
19. [Multiple myeloma causing obstructive jaundice by extramedullary plasmacytoma after Bence Jones protein loss--an autopsy case report].
Hamamoto K; Kosaka C; Takeno M; Anzai N; Tezuka H; Konishi H; Yagiri Y; Ueda Y
Rinsho Ketsueki; 1990 Jan; 31(1):57-61. PubMed ID: 2179601
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
